JP2013545459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545459A5 JP2013545459A5 JP2013537859A JP2013537859A JP2013545459A5 JP 2013545459 A5 JP2013545459 A5 JP 2013545459A5 JP 2013537859 A JP2013537859 A JP 2013537859A JP 2013537859 A JP2013537859 A JP 2013537859A JP 2013545459 A5 JP2013545459 A5 JP 2013545459A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- fviii
- seq
- factor viii
- hemophilia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 claims description 60
- 102000001690 Factor VIII Human genes 0.000 claims description 60
- 229960000301 factor viii Drugs 0.000 claims description 60
- 208000009292 Hemophilia A Diseases 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 208000031220 Hemophilia Diseases 0.000 claims description 14
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 102000057593 human F8 Human genes 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 3
- 208000013633 acquired hemophilia Diseases 0.000 claims description 3
- 229960000900 human factor viii Drugs 0.000 claims description 3
- 102000003712 Complement factor B Human genes 0.000 claims description 2
- 108090000056 Complement factor B Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 241000282898 Sus scrofa Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41043710P | 2010-11-05 | 2010-11-05 | |
| US61/410,437 | 2010-11-05 | ||
| PCT/US2011/059297 WO2012061689A2 (en) | 2010-11-05 | 2011-11-04 | A new variant of antihemophilic factor viii having increased specific activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545459A JP2013545459A (ja) | 2013-12-26 |
| JP2013545459A5 true JP2013545459A5 (enExample) | 2014-12-11 |
| JP5922141B2 JP5922141B2 (ja) | 2016-05-24 |
Family
ID=46025129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537859A Expired - Fee Related JP5922141B2 (ja) | 2010-11-05 | 2011-11-04 | 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9150637B2 (enExample) |
| EP (1) | EP2635297B1 (enExample) |
| JP (1) | JP5922141B2 (enExample) |
| KR (1) | KR101948337B1 (enExample) |
| CN (1) | CN103298483B (enExample) |
| AU (1) | AU2011323236B2 (enExample) |
| BR (1) | BR112013011041B1 (enExample) |
| CA (1) | CA2816575C (enExample) |
| CO (1) | CO6720990A2 (enExample) |
| DK (1) | DK2635297T3 (enExample) |
| EA (1) | EA035447B1 (enExample) |
| ES (1) | ES2721478T3 (enExample) |
| IL (1) | IL226158B (enExample) |
| MX (2) | MX347503B (enExample) |
| MY (1) | MY165089A (enExample) |
| SG (2) | SG10201509149VA (enExample) |
| WO (1) | WO2012061689A2 (enExample) |
| ZA (1) | ZA201303816B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2819123T3 (es) | 2015-01-30 | 2021-04-15 | Univ Emory | Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos |
| KR102219859B1 (ko) | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348384A (en) | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| MX9203440A (es) | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| JPS6281327A (ja) | 1985-10-04 | 1987-04-14 | Green Cross Corp:The | 人トロンビン製剤の加熱処理方法 |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| JPS6485927A (en) | 1987-09-29 | 1989-03-30 | Green Cross Corp | Hepatitis b vaccine |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| JPH0626980Y2 (ja) | 1987-11-26 | 1994-07-20 | ソニー株式会社 | 誤消去防止機構 |
| WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
| DK162233C (da) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| US5384132A (en) | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5888974A (en) | 1992-04-07 | 1999-03-30 | Emory University | Hybrid human/animal factor VIII |
| ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| WO1994029471A1 (en) * | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| JPH0899999A (ja) | 1994-09-30 | 1996-04-16 | Chemo Sero Therapeut Res Inst | α１プロテアーゼインヒビターの製造方法 |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| WO1997003191A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| PT1754718E (pt) * | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| JP2002517180A (ja) | 1997-12-05 | 2002-06-18 | ジ・イミユーン・リスポンス・コーポレーシヨン | 増大された発現を示す新規ベクターおよび遺伝子 |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| EP1820516B1 (en) | 1999-02-22 | 2013-07-24 | University of Connecticut | Novel albumin-free factor VIII formulations |
| EP1194161B1 (en) | 1999-07-13 | 2005-11-23 | Biovitrum Ab | Stable factor viii compositions |
| US6333192B1 (en) | 1999-08-09 | 2001-12-25 | North Carolina State University | Method of producing an undifferentiated avian cell culture using avian primordial germ cells |
| US6586574B1 (en) | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
| US7576182B1 (en) | 1999-08-31 | 2009-08-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PL206105B1 (pl) | 2000-09-19 | 2010-07-30 | Emory Universityemory University | Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej |
| DE60230456D1 (de) * | 2001-10-05 | 2009-01-29 | Expression Therapeutics Llc | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren |
| US20040249134A1 (en) | 2001-11-30 | 2004-12-09 | Lollar John S. | Factor viii c2 domain variants |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
| US7939634B2 (en) * | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| PL1750733T3 (pl) | 2004-05-03 | 2014-05-30 | Univ Emory | Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B |
| DK2371856T3 (en) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| WO2009075772A1 (en) | 2007-12-06 | 2009-06-18 | Wyeth | Crystal structure of human factor viii and uses thereof |
-
2011
- 2011-11-04 BR BR112013011041-4A patent/BR112013011041B1/pt active IP Right Grant
- 2011-11-04 MX MX2013005047A patent/MX347503B/es active IP Right Grant
- 2011-11-04 CN CN201180063748.0A patent/CN103298483B/zh active Active
- 2011-11-04 EA EA201390654A patent/EA035447B1/ru not_active IP Right Cessation
- 2011-11-04 EP EP11838863.6A patent/EP2635297B1/en active Active
- 2011-11-04 SG SG10201509149VA patent/SG10201509149VA/en unknown
- 2011-11-04 US US13/883,244 patent/US9150637B2/en active Active
- 2011-11-04 SG SG2013034137A patent/SG190136A1/en unknown
- 2011-11-04 JP JP2013537859A patent/JP5922141B2/ja not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059297 patent/WO2012061689A2/en not_active Ceased
- 2011-11-04 AU AU2011323236A patent/AU2011323236B2/en active Active
- 2011-11-04 DK DK11838863.6T patent/DK2635297T3/da active
- 2011-11-04 MY MYPI2013001627A patent/MY165089A/en unknown
- 2011-11-04 CA CA2816575A patent/CA2816575C/en active Active
- 2011-11-04 KR KR1020137014351A patent/KR101948337B1/ko active Active
- 2011-11-04 ES ES11838863T patent/ES2721478T3/es active Active
- 2011-11-04 MX MX2016015430A patent/MX351220B/es unknown
-
2013
- 2013-05-05 IL IL226158A patent/IL226158B/en active IP Right Grant
- 2013-05-24 ZA ZA2013/03816A patent/ZA201303816B/en unknown
- 2013-06-05 CO CO13136450A patent/CO6720990A2/es unknown
-
2015
- 2015-08-25 US US14/834,769 patent/US10053500B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The first-in-class peptide binder to the SARS-CoV-2 spike protein | |
| DK2864360T3 (en) | TARGETED THERAPY | |
| CN110612118B (zh) | 用于引起针对hbv的免疫应答的病毒样粒子 | |
| JP2010516290A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2011528332A (ja) | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 | |
| EA019516B1 (ru) | Лечение микробных инфекций | |
| JP2015520188A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| CN102292346A (zh) | 肥胖的治疗 | |
| CN108883166A (zh) | 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗 | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| CN109153720B (zh) | 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断 | |
| US12006343B2 (en) | C4BP-based compounds for treating immunological diseases | |
| JP2010535504A5 (enExample) | ||
| CN102088992B (zh) | 肽基二酰基甘油酯 | |
| CN108699548A (zh) | 将生物包封于植物细胞中的治疗性蛋白质靶向递送至目标细胞类型以治疗疾病 | |
| JP2020536925A5 (enExample) | ||
| JP2023515806A5 (enExample) | ||
| JP2023544409A5 (enExample) | ||
| CN104755095A (zh) | 用于伤口治疗的药物 | |
| WO2023125600A1 (zh) | 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品 | |
| Fan et al. | A cleaved adhesin DNA vaccine targeting dendritic cell against Porphyromonas gingivalis–induced periodontal disease | |
| JP7691414B2 (ja) | メタロプロテアーゼａｄａｍｔｓ－７の免疫原性ペプチドセグメント、ならびに抗アテローム性動脈硬化症及び関連疾患におけるその使用 |